Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.67 |
| ▸ | CSF1R | P07333 | 3/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | BTK | Q06187 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5004557 | 0.99 | PTGS1 (0.68) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL10092868 | 0.90 | CSF1R (0.55) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL2313285 | 0.90 | MAPT (0.68) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL22025296 | 0.90 | PTGS1 (0.70) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL30822434 | 0.90 | PTGS1 (0.70) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL1358527 | 0.88 | HDAC3 (0.58) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL12858422 | 0.88 | MEN1 (0.73) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL1454873 | 0.87 | PTGS1 (0.63) | PTGS1MEN1HTTRAB9AKMT2A | |
| SCHEMBL22025295 | 0.87 | PTGS1 (0.64) | PTGS1MEN1RAB9AKMT2AKIT | |
| SCHEMBL24249928 | 0.86 | MEN1 (0.70) | PTGS1MEN1HTTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| EP-3150593-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2011-03-03 | — | — | US | claimed |
| US-7795273-B2 | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| EP-2222162-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute (US) | 2010-09-01 | — | — | EP | claimed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | claimed |
| EP-2170842-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM, LLC (BM) | 2010-04-07 | — | — | EP | claimed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| EP-2079702-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2007065664-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | claimed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | claimed |
| JP-2007504159-A | — | — | 2007-03-01 | — | — | JP | claimed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | PTGS1 2963/4885MEN1 4175/4885HTT 4201/4885 |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | MAP4K2, MAP4K3, MAP4K1 | PTGS1 958/4885MEN1 3441/4885HTT 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.